

1 the Federal Food, Drug, and Cosmetic Act (21
2 U.S.C. 353(b)(1)).

3 (b) **FEE WAIVER.**—The Secretary shall waive the fee
4 under section 736(a)(1) of the Federal Food, Drug, and
5 Cosmetic Act (21 U.S.C. 379h(a)(1)) with respect to a
6 supplemental application that receives priority review
7 under subsection (a).

8 (c) **OVER-THE-COUNTER AVAILABILITY.**—Notwith-
9 standing any other provision of law, with respect to indi-
10 viduals under age 18, a contraceptive drug that is eligible
11 for priority review under subsection (a) shall be subject
12 to section 503(b)(1) of the Federal Food, Drug, and Cos-
13 metic Act (21 U.S.C. 353(b)(1)), including after approval
14 of the supplemental application as described in subsection
15 (a)(3).

16 (d) **APPLICABILITY.**—This section applies with re-
17 spect to a supplemental application described in subsection
18 (a) that—

19 (1) is submitted before the date of enactment of
20 this Act and remains pending as of such date of en-
21 actment; or

22 (2) is submitted after such date of enactment.

Amend the title to read as follows: “A bill to increase access to safe and effective oral contraceptives, and for other purposes.”.

